{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:26:12Z","timestamp":1764951972823,"version":"3.46.0"},"reference-count":10,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T00:00:00Z","timestamp":1762646400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cancer Policy"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.jcpo.2025.100666","type":"journal-article","created":{"date-parts":[[2025,11,9]],"date-time":"2025-11-09T15:48:49Z","timestamp":1762703329000},"page":"100666","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Overall survival as a safety guardrail in cancer drug trials"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9788-1868","authenticated-orcid":false,"given":"Rashidul Alam","family":"Mahumud","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcpo.2025.100666_bib1","unstructured":"US Food and Drug Administration. Approaches to Assessment of Overall Survival in Oncology Clinical Trials \u2014 Draft Guidance for Industry. \u3008https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/approaches-assessment-overall-survival-oncology-clinical-trials\u3009."},{"key":"10.1016\/j.jcpo.2025.100666_bib2","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2017.11.014","article-title":"Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review","volume":"123","author":"Savina","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.jcpo.2025.100666_bib3","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.17547","article-title":"Correlation between surrogate end points and overall survival in a multi-institutional clinicogenomic cohort of patients with non small cell lung or colorectal cancer","volume":"4","author":"Kehl","year":"2021","journal-title":"JAMA Netw. Open"},{"key":"10.1016\/j.jcpo.2025.100666_bib4","first-page":"1","article-title":"Regulatory and clinical consequences of negative confirmatory trials of accelerated approval cancer drugs: retrospective obser- vational study","volume":"374","author":"Gyawali","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jcpo.2025.100666_bib5","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(23)00357-1","article-title":"Withdrawn accelerated approvals for cancer indications in the USA: what is the marketing authorisation status in the EU","volume":"24","author":"Cramer","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.jcpo.2025.100666_bib6","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1001\/jamaoncol.2022.7770","article-title":"Exposure to US cancer drugs with lack of confirmed benefit after US food and drug administration accelerated approval","volume":"9","author":"Parikh","year":"2023","journal-title":"JAMA Oncol."},{"issue":"4","key":"10.1016\/j.jcpo.2025.100666_bib7","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/EVIDoa2200195","article-title":"Meta-Analysis of candidate surrogate end points in advanced prostate cancer","volume":"2","author":"Gharzai","year":"2023","journal-title":"NEJM Evid."},{"issue":"ember 2017","key":"10.1016\/j.jcpo.2025.100666_bib8","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.critrevonc.2017.11.014","article-title":"Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review","volume":"123","author":"Savina","year":"2018","journal-title":"Crit. Rev. Oncol. Hematol."},{"issue":"7","key":"10.1016\/j.jcpo.2025.100666_bib9","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1001\/jamaoncol.2016.5296","article-title":"Overall survival in cancer drug trials as a new surrogate end point for overall survival in the real world","volume":"3","author":"Mailankody","year":"2017","journal-title":"JAMA Oncol."},{"issue":"25","key":"10.1016\/j.jcpo.2025.100666_bib10","first-page":"1","article-title":"Overall survival assessment in cancer drug trials: a luxury or a necessity","volume":"2045","author":"Stevens","year":"2025","journal-title":"Lancet Oncol."}],"container-title":["Journal of Cancer Policy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325001109?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2213538325001109?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,5]],"date-time":"2025-12-05T16:21:14Z","timestamp":1764951674000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2213538325001109"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":10,"alternative-id":["S2213538325001109"],"URL":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100666","relation":{},"ISSN":["2213-5383"],"issn-type":[{"type":"print","value":"2213-5383"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Overall survival as a safety guardrail in cancer drug trials","name":"articletitle","label":"Article Title"},{"value":"Journal of Cancer Policy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcpo.2025.100666","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"100666"}}